EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS

Elisa Gobbini, Alexandra Langlais, Pascale Missy, Sébastien Chanoine, Benjamin Besse, Pierre-Jean Souquet, Fabrice Barlesi, Clarisse Audigier-Valette, Anne-Cécile Métivier, Isabelle Monnet, José Hureaux, Gaelle Jeannin und 8 weitere

European Journal of Cancer · 2025

DOI: 10.1016/j.ejca.2025.115560 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Elisa Gobbini und 19 weiteren Autor:innen. Beteiligte Einrichtung: Curie-Montsouris Thorax Institute, Institut Curie, Paris, France. Electronic address: elisa.gobbini@curie.fr. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Metformin, Morphine. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bristol-Myers Squibb Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Most patients with lung cancer have comorbidities at the time of diagnosis. Treatments prescribed for cancer-related symptoms are thus added to drugs for chronic diseases. The impact of comedication on immunotherapy efficacy has been studied in retrospective series, but the results are often biased by the lack of information on the independent prognostic impact of comedication weighted for comorbidities and disease aggressiveness. METHODS: The IFCT-1502 CLINIVO study is a nationwide retrospective cohort of patients with advanced non-small cell lung cancer who received nivolumab in second or later lines of treatment as part of the French Expanded Access Program. We retrieved comedication prescriptions from 90 days before to 30 days after the first nivolumab administration via the French national healthcare database. We report the results of a comprehensive post hoc analysis investigating the impact of comedication on treatment response considering well-known negative prognostic factors. RESULTS: We selected 753 patients whose medical and comedication records were available. According to the multivariate analysis, morphine and corticosteroids > 20 mg per day were associated with poor overall survival regardless of disease aggressiveness. Conversely, metformin was associated with better overall survival. Morphine and corticosteroids were also found to be associated with shorter real-world progression-free survival according to multivariate analysis, as were poor prognostic factors such as liver metastasis and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score ≥ 2. CONCLUSION: Our study confirmed the negative impact of morphine and high-dose corticosteroids on immunotherapy efficacy regardless of poor prognostic factors related to disease aggressiveness. On the other hand, our findings suggested a positive impact of metformin on immunotherapy outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsMetforminMorphineImmunotherapyNivolumabImmune Checkpoint InhibitorsHumansMaleFemaleRetrospective StudiesAgedMiddle AgedAged, 80 and overTreatment OutcomeFrance

Stichwörter der Autor:innen

ComedicationDrug interactionImmunotherapyNSCLC

Substanzen

MetforminMorphineNivolumabImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Curie-Montsouris Thorax Institute, Institut Curie, Paris, France. Electronic address: elisa.gobbini@curie.fr.
  • Intergroupe Francophone de Cancérologie Thoracique (IFCT), France.
  • Grenoble-Alpes University Hospital, Pharmacology Unit, Grenoble, France.
  • Gustave Roussy Institute, Medical Oncology Department, Villejuif, France.
  • Centre hospitalier de Lyon Sud, Pulmonology Unit, Lyon, France.
  • Gustave Roussy Institute, Medical Oncology Department, Villejuif, France; Paris Saclay University, Faculty of Medicine, Kremlin-Bicêtre, France.

Förderung

  • Bristol-Myers Squibb Company

Zitieren

APA

Gobbini, E., Langlais, A., Missy, P., Chanoine, S., Besse, B., Souquet, P. J., Barlesi, F., Audigier-Valette, C., Métivier, A. C., Monnet, I., Hureaux, J., Jeannin, G., Cadranel, J., Lagrange, A., Tran, Q., Morin, F., Molinier, O., Westeel, V., Girard, N., & Moro-Sibilot, D. (2025). Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115560

Vancouver

Gobbini E, Langlais A, Missy P, Chanoine S, Besse B, Souquet PJ, et al. Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115560

BibTeX
@article{Gobbini2025,
  author = {Gobbini, Elisa and Langlais, Alexandra and Missy, Pascale and Chanoine, Sébastien and Besse, Benjamin and Souquet, Pierre-Jean and Barlesi, Fabrice and Audigier-Valette, Clarisse and Métivier, Anne-Cécile and Monnet, Isabelle and Hureaux, José and Jeannin, Gaelle and Cadranel, Jacques and Lagrange, Aurélie and Tran, Quân and Morin, Franck and Molinier, Olivier and Westeel, Virginie and Girard, Nicolas and Moro-Sibilot, Denis},
  title = {Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS},
  journal = {European Journal of Cancer},
  year = {2025},
  doi = {10.1016/j.ejca.2025.115560}
}
Kostenlos starten →